Drug attitude in adolescents: A key factor for a comprehensive assessment

Journal of Clinical Psychopharmacology

Volumn 34, Issue 1, 2014, Pages 99-108

  Molteni, Silvia ^a   Giaroli, Giovanni ^b,c   Rossi, Giorgio ^d   Comelli, Mario ^a   Rajendraprasad, Maneesh ^b   Balottin, Umberto ^a,d  

^a UNIVERSITY OF PAVIA   (Italy)

^b NORTH EAST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

Author keywords

Adolescence; Antipsychotic drugs; Compliance; Drug Attitude Inventory (DAI); Psychosis; Subjective experience

Indexed keywords

AMISULPRIDE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ARIPIPRAZOLE; BENZODIAZEPINE DERIVATIVE; CENTRAL STIMULANT AGENT; CLOZAPINE; HALOPERIDOL; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADOLESCENT; ADULT; AKATHISIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; ATTITUDE; AUTISM; BARNES AKATHISIA SCALE; BIPOLAR DISORDER; BORDERLINE STATE; BRADYKINESIA; BRIEF PSYCHOTIC DISORDER; CLINICAL EVALUATION; CLINICAL GLOBAL IMPRESSION SCALE; CONDUCT DISORDER; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSKINESIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; ITALY; LIKERT SCALE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; MENTAL PATIENT; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSESSIVE COMPULSIVE DISORDER; PARANOID PERSONALITY DISORDER; PATIENT ASSESSMENT; PATIENT COMPLIANCE; PERSONAL EXPERIENCE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOSIS; QUALITY OF LIFE; QUALITY OF LIFE INDEX; RESTLESSNESS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TREMOR; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; YOUNG ADULT;

ADOLESCENT; ADOLESCENT BEHAVIOR; AGE FACTORS; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; GREAT BRITAIN; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; ITALY; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MULTIVARIATE ANALYSIS; ODDS RATIO; QUALITY OF LIFE; QUESTIONNAIRES; RISK FACTORS;

EID: 84891748856     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000035     Document Type: Article

References (41)

1. Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(suppl 7):29-40.
2. Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9-20.
3. Vitiello B, Correll C, van Zwieten-Boot B, et al. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol. 2009;19(9):629-635.
4. Swanson J. Compliance with stimulants for attention-deficit/hyperactivity disorder: issues and approaches for improvement. CNS Drugs. 2003;17(2):117-131.
5. Sarwer-Foner GJ. On the mechanisms of the action of neuroleptic drugs: a theoretical psychodynamic explanation. Recent Adv Biol Psychiatry. 1963;6:217-232.
6. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071.
7. Lambert M, Conus P, Cotton S, et al. Prevalence, predictors, and consequences of long-term refusal of antipsychotic treatment in first-episode psychosis. J Clin Psychopharmacol. 2010;30(5):565-572.
8. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(suppl 4):1-46.
9. Awad AG, Hogan TP. Subjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl. 1994;380:27-32.
10. Balestrieri M, Giaroli G, Mazzi M, et al. Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients. Pharmacopsychiatry. 2006;39(3):81-84.
11. Awad AG. Drug therapy in schizophreniaVvariability of outcome and prediction of response. Can J Psychiatry. 1989;34(7):711-720.
12. Jaspers K. Allgemeine Psychopathologie. Berlin: Springer Verlag; 1959. Berlin. Italian edition: Roma: Il Pensiero Scientifico editore; 1964.
13. Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl). 2002;162(1):3-10.
14. Gaebel W, Riesbeck M, von Wilmsdorff M, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010;20(5):310-316.
15. Ritsner M, Gibel A, Perelroyzen G, et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol. 2004;24(6): 582-591.
16. Lambert M, Schimmelmann BG, Schacht A, et al. Differential 3-year effects of first-versus second-generation antipsychotics on subjective well-being in schizophrenia using marginal structural models. J Clin Psychopharmacol. 2011;31(2):226-230.
17. Schimmelmann BG, Paulus S, Schacht M, et al. Subjective distress related to side effects and subjective well-being in first admitted adolescents with early-onset psychosis treated with atypical antipsychotics. J Child Adolesc Psychopharmacol. 2005;15(2): 249-258.
18. Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol. 1995;10(suppl 3):133-138.
19. Fraguas D, Llorente C, Rapado-Castro M, et al. Attitude toward antipsychotic medication as a predictor of antipsychotic treatment discontinuation in first-episode early-onset psychosis. Rev Psiquiatr Salud Ment. 2008;1(1):10-17.
20. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983;13(1):177-183.
21. Townsend L, Floersch J, Findling RL. Adolescent attitudes toward psychiatric medication: the utility of the Drug Attitude Inventory. J Child Psychol Psychiatry. 2009;50(12):1523-1531.
22. Floersch J, Townsend L, Longhofer J, et al. Adolescent experience of psychotropic treatment. Transcult Psychiatry. 2009;46(1):157-179.
23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261-276.
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(suppl 20):22-33.
25. First MB, Gibbon M, Spitzer RL, et al. Structured Clinical Interview for DSM-IV Axis II Personality Disorders, (SCID-II). Washington, DC: American Psychiatric Press, Inc; 1997.
26. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005;76(2-3):247-265.
27. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672-676.
28. GuyW. ECDEU. Assessment Manual for Psychopharmacology, revised. U.S. Department of Health, Education, and Welfare publication (ADM), 76-338. Rockville, MD: National Institute of Mental Health; 1976:218-222.
29. Shaffer D, Gould MS, Brasic J, et al. A children's global assessment scale (CGAS). Arch Gen Psychiatry. 1983;40(11):1228-1231.
30. EuroQol Group. EuroQolVa new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199-208.
31. Harrell FE. Regression Modeling Strategies. New York, NY: Springer Verlag Inc; 2001.
32. Babyak MA. What you see may not be what you get: a brief, nontechnical introduction to overfitting in regression-type models. Psychosom Med. 2004;66:(3): 411-421.
33. R: A language and environment for statistical computing [computer program]. Version 2.13.1. Vienna, Austria: R Foundation for Statistical Computing, R Core Team; 2011.
34. Mizrahi R, Bagby RM, Zipursky RB, et al. How antipsychotics work: the patients' perspective. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(5):859-864.
35. Gervin M, Browne S, Garavan J, et al. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry. 1999;14(7):405-409.
36. Seale C, Chaplin R, Lelliott P, et al. Antipsychotic medication, sedation and mental clouding: an observational study of psychiatric consultations. Soc Sci Med. 2007;65(4):698-711.
37. de Haan L, Nimwegen L, Amelsvoort T, et al. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry. 2008;41(4):125-128.
38. Murawiec S, Boutros NN. Correlation between early subjective response to antipsychotics and the number of hospitalizations and hospitalization days in a period of 10-11 years in schizophrenia patients. Neuropsychobiology. 2012;66(2):120-125.
39. Yang J, Ko YH, Paik JW, et al. Symptom severity and attitudes toward medication: impacts on adherence in outpatients with schizophrenia. Schizophr Res. 2012;134(2-3):226-231.
40. Correll CU, Penzner JB, Parikh UH, et al. Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolesc Psychiatr Clin N Am. 2006;15:177-206.
41. Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry. 2004;65(7):932-939.